Related Experiment Videos
Hematopoietic growth factors. Defining the appropriate clinical role in multimodality cancer therapy
1Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Boston, USA.
Abstract:
Laboratory investigations have begun to elucidate the regulatory molecules that control the processes of blood cell growth and differentiation. Recombinant human colony-stimulating factors are examples of biotechnology-produced molecules that have epitomized the translation of such basic scientific investigation into therapeutic advances. Small cell lung cancer, a malignancy that is overall highly sensitive to aggressive myelosuppressive chemotherapy at initial presentation, has been used as a clinical model in which the activity of human colony-stimulating factors has been tested. In this article, the clinical applications of hematopoietic growth factors are reviewed in brief. The appropriate clinical use of these agents may allow novel therapeutic strategies to be developed in a research setting. Similarly, these agents have the potential to improve supportive care and improve certain clinical outcomes in the non-research clinical care of patients. Issues of cost of treatment are raised by these agents, but the true clinical value of hematopoietic growth factors needs to be studied more rigorously, with emphasis on quality of life and redistribution of care costs outside of hospitals before definitive statements can be made.
Insights
Hematopoietic growth factors, like recombinant human colony-stimulating factors, show promise in cancer therapy and supportive care. Further research is needed to confirm their clinical value, focusing on quality of life and cost-effectiveness.
Area of Science:
- Biotechnology and Hematology
- Molecular Biology and Oncology
Background:
- Laboratory research is identifying regulatory molecules controlling blood cell growth and differentiation.
- Biotechnology has produced recombinant human colony-stimulating factors, translating basic science into therapeutics.
- Small cell lung cancer serves as a model for testing human colony-stimulating factors due to its sensitivity to chemotherapy.
Purpose of the Study:
- To review the clinical applications of hematopoietic growth factors.
- To explore their potential in novel therapeutic strategies and supportive care.
- To discuss the need for rigorous evaluation of their clinical value and cost-effectiveness.
Main Methods:
- Review of clinical applications of hematopoietic growth factors.
- Analysis of their use in research settings and non-research clinical care.
- Consideration of cost-effectiveness and quality of life impacts.
Main Results:
- Hematopoietic growth factors represent a therapeutic advance from basic scientific investigation.
- These agents can potentially improve supportive care and clinical outcomes.
- Their use may enable novel therapeutic strategies in research settings.
Conclusions:
- Appropriate clinical use of hematopoietic growth factors can enhance cancer treatment.
- Further rigorous studies are essential to determine true clinical value, including quality of life and cost redistribution.
- More research is needed before definitive statements on their overall clinical utility can be made.